Don’t Trade in the Dark—Get Your Pre-Market Report Every Day.Join Now
Healthcare | Small Cap
Health Score : 3.45Sanofi India Ltd. presents a mixed financial picture, characterized by exceptional stability but significant performance challenges. The company's greatest strength is its virtually debt-free status, which provides a strong cushion against financial risks and economic volatility. Operationally, it appears to manage its inventory and customer payments with notable efficiency. However, these strengths are contrasted by considerable weaknesses in key areas. The company is currently experiencing a lack of growth across revenues, profits, and assets, indicating a period of stagnation. Profitability is a major concern, with margins and returns on investment being very low. Furthermore, its capacity to cover short-term expenses with available liquid cash is limited. The future outlook is one of stability without growth; while the company is not in immediate financial danger due to its low debt, its inability to expand and generate profits poses a significant long-term challenge.
Health Score : 3.45Sanofi India Ltd. presents a mixed financial picture, characterized by exceptional stability but significant performance challenges. The company's greatest strength is its virtually debt-free status, which provides a strong cushion against financial risks and economic volatility. Operationally, it appears to manage its inventory and customer payments with notable efficiency. However, these strengths are contrasted by considerable weaknesses in key areas. The company is currently experiencing a lack of growth across revenues, profits, and assets, indicating a period of stagnation. Profitability is a major concern, with margins and returns on investment being very low. Furthermore, its capacity to cover short-term expenses with available liquid cash is limited. The future outlook is one of stability without growth; while the company is not in immediate financial danger due to its low debt, its inability to expand and generate profits poses a significant long-term challenge.
Overall Valuation Score
Markets Depth NSE
Buy Orders
Bid
Quantity
Orders
No buy depth
Total
0
0
Sell Orders
Ask
Quantity
Orders
No sell depth
Total
0
0
Markets Today NSE
High
0.00
Low
0.00
Open
0.00
Close
0.00
Prev Close
0.00
Avg Price
0.00
Volume
0
Last Traded Quantity
0
Last Traded Time
N/A
Price Movement Indicator
Today's Low: 0.00
Today's High: 0.00
P/E RATIO (TTM)
23.45
Industry Median
35.50
Small Cap Median
24.51
P/E RATIO
17.56
P/B RATIO
8.44
Industry Median
11.94
Small Cap Median
8.44
P/S RATIO
3.65
Industry Median
7.76
Small Cap Median
3.65
Others
PEG RATIO
0.00
EV/EBITDA RATIO
12.41
The Calculations Shown Above Are Based on the Last Traded Price (LTP) of ₹3155 as on Sep 1, 2026.
Growth Score : 2.00The company's growth prospects appear weak across the board. The analysis reveals a lack of expansion in key areas, including sales, operating profits, and net income. Additionally, the company is not significantly growing its asset base, which suggests limited investment in future expansion. This overall stagnation is a significant concern, as it points to a business that is struggling to increase its market share or operational scale. A lack of growth can impact long-term competitiveness and shareholder value.
Revenue Growth RatePoorOperating Profit Growth RatePoorEarnings Per Share (EPS) GrowthPoorAsset Growth RatePoorNet Income Growth RatePoorRevenue Growth Rate
Operating Profit Growth Rate
Earnings Per Share (EPS) Growth
Asset Growth Rate
Net Income Growth Rate
Peer Comparison empowers investors to evaluate a company against its industry peers using key financial metrics like P/E ratio, EPS, and profit margins. It helps identify whether a company is overvalued, undervalued, or performing in line with competitors. Investors can use this data to spot opportunities, assess risks, and make informed decisions. This contextual view adds depth beyond standalone company analysis.
| NO | Company Name | Health Score | P/E Ratio | Valuation | OPM | EPS | Latest Profit & Loss |
|---|---|---|---|---|---|---|---|
| 1 | Granules India Ltd | 7.73 | 34.87 | Highly Overvalued | 1185.00 | 16.17 | 595.00 |
| 2 | FDC Ltd | 7.64 | 19.29 | Neutral | 346.00 | 17.56 | 281.00 |
| 3 | Supriya Lifescience Ltd | 7.46 | 30.91 | Overvalued | 294.00 | 25.98 | 209.00 |
| 4 | Aarti Pharmalabs Ltd | 7.46 | 44.90 | Neutral | 369.00 | 19.43 | 175.00 |
| 5 | Innova Captab Ltd | 7.36 | 43.37 | Overvalued | 243.00 | 14.63 | 141.00 |
| 6 | Akums Drugs & Pharmaceuticals Ltd | 7.28 | 48.06 | Overvalued | 522.00 | 7.09 | 256.00 |
| 7 | Marksans Pharma Ltd | 7.24 | 34.97 | Neutral | 601.00 | 6.64 | 420.00 |
| 8 | Hikal Ltd | 7.13 | -50.14 | Neutral | 220.00 | -3.95 | -49.00 |
| 9 | Shilpa Medicare Ltd | 5.94 | 71.52 | Highly Overvalued | 435.00 | 6.80 | 243.00 |
| 10 | Natco Pharma Ltd | 5.69 | 10.72 | Neutral | 1436.00 | 71.55 | 1418.00 |
| 11 | Strides Pharma Science Ltd | 5.55 | 16.97 | Undervalued | 925.00 | 19.92 | 575.00 |
| 12 | Jeena Sikho Lifecare Ltd | 5.52 | 28.20 | Neutral | 349.00 | 17.87 | 222.00 |
| 13 | Orchid Pharma Ltd | 4.85 | 234.05 | Neutral | 41.00 | 8.91 | 21.00 |
| 14 | Sequent Scientific Ltd | 4.61 | 301.49 | Overvalued | 162.00 | 1.74 | 32.00 |
| 15 | Sun Pharma Advanced Research Company Ltd | 4.35 | 4.12 | Neutral | 1599.00 | 47.83 | 1553.00 |
| 16 | Zota Health Care Ltd | 3.97 | -48.15 | Neutral | 19.00 | 8.06 | -74.00 |
| 17 | Sanofi India Ltd | 3.45 | 17.56 | Neutral | 491.00 | 134.52 | 413.00 |
| 18 | Procter & Gamble Health Ltd | 3.45 | 29.33 | Neutral | 466.00 | 215.00 | 357.00 |
0 Credits RemainingUnlock Deep Technical Insights in Seconds Only with Dhanarthi AI
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Market Sentiment
Analysis Driven By 26 Technical Indicators From The 1 Hour Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Analyzing moving average trends and crossovers. Green/Red badges indicate if the current condition passes or fails.
Comparing stock price performance (normalized) against benchmark indices over time.
Recent daily trading volume represented as a bar chart, alongside historical averages.
Current closing price relative to the 52-week highest and lowest prices.
Concall Report⬤5th Mar 26
Investor Conference Call – Feb 26, 2026
NEUTRAL SENTIMENT
Quarterly Report⬤25th Feb 26
Quarterly Financial Results Q3 FY 2025-26
BULLISH SENTIMENT
Sanofi India Ltd., a subsidiary of French multinational Sanofi S.A., is a prominent pharmaceutical company in India. It manufactures and markets a diverse portfolio of prescription drugs focusing on therapeutic areas such as diabetes, cardiovascular diseases, central nervous system disorders, and anti-infectives, catering to critical healthcare needs across the country.
P/E Ratio (TTM): Price to Earnings ratio shows how much an investor pays for every rupee of the company's earnings. Sanofi India Ltd's P/E ratio (TTM) is 23.45, compared to the industry median of 35.50 and large cap median of 24.51.
P/B Ratio: Price to Book ratio compares a company's market price to its book value per share. Sanofi India Ltd's P/B ratio is 8.44, compared to the industry median of 11.94 and large cap median of 8.44.
P/S Ratio: Price to Sales ratio compares a company's market value to its total revenue. Sanofi India Ltd's P/S ratio is 3.65, compared to the industry median of 7.76 and large cap median of 3.65.
PEG Ratio: PEG ratio adjusts the P/E ratio for expected earnings growth. Sanofi India Ltd's PEG ratio is 2.50.
EV/EBITDA Ratio: This ratio compares a company's enterprise value to its earnings before interest, tax, depreciation, and amortization. Sanofi India Ltd's EV/EBITDA ratio is 12.41.
Return on Equity (ROE): ROE measures how much profit a company generates from shareholders' invested capital. Sanofi India Ltd's ROE is N/A.
Return on Assets (ROA): ROA measures how efficiently a company converts its assets into net profit. Sanofi India Ltd's ROA is N/A.
Return on Capital Employed (ROCE): ROCE measures how efficiently a company generates profit from all the capital it employs. Sanofi India Ltd's ROCE is N/A.
Operating Margin: Operating margin shows what percentage of revenue remains after covering operating expenses. Sanofi India Ltd's operating margin is N/A.
Net Margin: Net margin shows what percentage of revenue converts into final net profit. Sanofi India Ltd's net margin is N/A.
Current Ratio: The current ratio measures a company's ability to pay short-term liabilities using short-term assets. Sanofi India Ltd's current ratio is N/A.
Debt to Equity Ratio: This ratio shows the proportion of debt a company uses relative to shareholders' equity. Sanofi India Ltd's debt-to-equity ratio is N/A.
Interest Coverage Ratio: This ratio shows how easily a company can pay interest on its outstanding debt from its operating earnings. Sanofi India Ltd's interest coverage ratio is N/A.
Dividend Per Share (DPS): DPS shows the total dividend paid per share in the latest financial year. Sanofi India Ltd's DPS is ₹117.
Earnings Per Share (EPS): EPS shows how much profit is allocated to each outstanding share. Sanofi India Ltd's EPS is N/A.
(Source line: "Ratios as of 25 Sept 2026, based on last traded price of ₹3155. Data sourced from BSE/NSE Exchange Filings & Public Terminal Data.")
Founded: 1956 (as Hoechst Fedco Pharma Private Limited)
Headquarters: Mumbai, Maharashtra
Core Offerings: Diabetes care products, Cardiovascular medicines, Central Nervous System (CNS) drugs, Anti-infectives, Pain & Inflammation management
Stock Listing: NSE (SANOFI), BSE (500674)
Promoter: Sanofi S.A.
1956: Incorporated as Hoechst Fedco Pharma Private Limited. 1980: Renamed Hoechst India Limited. 2002: Renamed Aventis Pharma Limited following global mergers and acquisitions of its parent entities. 2010: Renamed Sanofi India Limited, aligning with the global parent brand, Sanofi S.A. Present: Continues its legacy as a leading pharmaceutical player in India, focusing on innovation and established products across various therapeutic areas.
| Segment Name | Revenue % | EBITDA |
|---|---|---|
| Pharmaceutical Products | 100% | Operating Profit |
Pharmaceutical Products: Manufactures and markets a diverse portfolio of prescription drugs across key therapeutic areas including diabetes, cardiovascular diseases, anti-infectives, CNS disorders, and pain management, serving both domestic and international markets.
Manufacturing & Supply Chain: Operates robust manufacturing facilities in India (e.g., Ankleshwar, Goa) for producing formulations, ensuring a strong and efficient supply chain for its products.
Sales & Marketing: Employs a dedicated sales force and undertakes targeted marketing strategies to promote its key brands and ensure widespread reach and patient access across India.
Rodolfo Hrosz - Managing Director & Head of India. Mr. Hrosz brings extensive international experience from various leadership roles within Sanofi across different markets, driving growth and strategic initiatives for the Indian operations.
No major material subsidiaries reported as separately listed entities under Sanofi India Ltd. The operations are largely consolidated within the parent entity.
Notable corporate actions include the divestment of its Ankleshwar manufacturing facility in 2020 and the sale of its consumer healthcare business to an unlisted affiliate (Sanofi Healthcare India Private Limited) in 2021. In 2023, the company announced plans for a merger with Sanofi Healthcare India Private Limited.
The Sanofi India Ltd share price today is ₹3155 on NSE (SANOFI), as of 26 Sept 2026.
As of 25 Sept 2026, Sanofi India Ltd share price is ₹3155, with previous close ₹3155. Today's range is ₹3155 to ₹3155. The 52-week range is ₹3049 to ₹4434.30.
As of today, Sanofi India Ltd's market cap is ₹7,351.15 crore (Mid Cap).
Sanofi India Ltd's current P/E ratio is 23.45, compared to the PHARMACEUTICALS & BIOTECHNOLOGY sector average of 37.50.
Sanofi India Ltd's current P/B ratio is 8.44.
Sanofi India Ltd's current dividend yield is 3.71%. Last dividend of ₹117.00 per share was declared on 23-Apr-2024.
Sanofi India Ltd's EPS (TTM) is ₹N/A.
Sanofi India Ltd., a subsidiary of French multinational Sanofi S.A., is a prominent pharmaceutical company in India. It manufactures and markets a diverse portfolio of prescription drugs focusing on therapeutic areas such as diabetes, cardiovascular diseases, central nervous system disorders, and anti-infectives, catering to critical healthcare needs across the country.
Sanofi India Ltd is promoted by Sanofi S.A., holding 60.4% as of 25 Sept 2026.
Sanofi India Ltd is listed on NSE (SANOFI) and BSE (500674). Its next quarterly results are expected on August 2024.
Capital Expenditures (CapEx)
